• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[The clinical use of the prostate-specific antigen in patients with prostatic cancer].

作者信息

Matveev B P, Sokolov A V, Bukharkin B V, Ledian K M, Tilk A E, Makarova G V

出版信息

Urol Nefrol (Mosk). 1991 Jul-Aug(4):8-12.

PMID:1719686
Abstract

Radioimmunoassay determination of prostatic-specific antigen (PSA) was conducted in 71 patients with prostatic cancer varying in stages. 85 serum samples were investigated. Of 21 newly diagnosed cases PSA was elevated in 16 (76.2%). No significant elevation of the marker was noticed in stage II patients, while at stage III and IV PSA levels were universally increased. The mean PSA level for stage III was 149.5 ng/ml, for stage IV 291.4 ng/ml. Two stage II patients in remission out of ten presented with high PSA concentrations, while in partial remission this was observed in 3 cases out of 9.50% occurrence of PSA elevated level was registered for stage III patients in remission, 100% occurrence in progression. Prostatic cancer stage IV manifested high PSA levels in 33% of cases under stabilization and in 100% in progression.

摘要

相似文献

1
[The clinical use of the prostate-specific antigen in patients with prostatic cancer].
Urol Nefrol (Mosk). 1991 Jul-Aug(4):8-12.
2
[Prostatic specific antigen for detection and monitoring of prostatic cancer].用于前列腺癌检测与监测的前列腺特异性抗原
Harefuah. 1992 Mar 15;122(6):345-8, 408.
3
Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.前列腺特异性抗原:在前列腺癌诊断和管理中的临床应用
Geriatrics. 1992 Sep;47(9):26-32.
4
Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.未治疗的前列腺癌和良性前列腺增生中前列腺特异性抗原和前列腺酸性磷酸酶的评估。
Scand J Urol Nephrol Suppl. 1991;138:97-103.
5
[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].[前列腺特异性抗原在局限性前列腺腺癌诊断中的作用。奈良泌尿肿瘤研究组]
Hinyokika Kiyo. 1996 Oct;42(10):795-804.
6
Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?前列腺上皮内瘤变(PIN)、前列腺癌和良性前列腺增生(BPH)患者的血清游离PSA和总PSA值。游离/总PSA是否为潜伏性和显性癌症的潜在检测指标?
Anticancer Res. 1997 May-Jun;17(3A):1531-4.
7
[Prostate-specific antigen (PSA): diagnostic and prognostic implications in the evaluation of carcinoma of the prostate].[前列腺特异性抗原(PSA):在前列腺癌评估中的诊断和预后意义]
Arch Ital Urol Nefrol Androl. 1989 Mar;61(1):29-36.
8
Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.未治疗和已治疗前列腺肿瘤中细胞增殖标志物(TPS)、自然杀伤(NK)活性与肿瘤负荷血清检测指标(PSA)的相关性
Anticancer Res. 1993 Jan-Feb;13(1):215-8.
9
Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.肿瘤标志物。局限性前列腺癌诊断与预后参数共识会议。瑞典斯德哥尔摩,1993年5月12 - 13日。
Scand J Urol Nephrol Suppl. 1994;162:73-87; discussion 115-27.
10
[Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].[测定前列腺特异性抗原和前列腺酸性磷酸酶作为前列腺癌的肿瘤标志物]
Arch Esp Urol. 1989;42 Suppl 2:124-30.